Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
May 11, 2023
- Kyowa Kirin Cuts Net Profit Forecast after Kidney Disease Drug Jettisoned
May 11, 2023
- Shionogi Hits Record High Earnings on Xocova Boon in FY2022
May 11, 2023
- Opdivo-Yervoy Shows Similar Mortality Rates in Registration Trial and RWD: Ono
May 11, 2023
- Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief
May 11, 2023
- Ono Notches Two-Digit Growth in FY2022; Opdivo en Route to 150 Billion Yen Mark
May 11, 2023
- Japan Ethical Drug Sales Surge 3.9% in March: Crecon
May 11, 2023
- Roche’s Diagnostic Gets Japan Coverage to Identify HER2 Low Breast Cancer Patients Eligible for Enhertu
May 10, 2023
- Trulicity Shipment Control Continues, Lilly Calls for Use of Novo Drugs
May 10, 2023
- Eisai Cuts FY2022 Earnings Forecast on FX, Subpar Mainstay Results
May 10, 2023
- Opdivo Best-Selling Med in Japan for 16 Months Straight: Encise
May 10, 2023
- PeptiDream Unit Seeks Label Expansion for PET Diagnostic Amyvid
May 9, 2023
- Over 40% of Japan Drug Makers Allow Side Jobs, MSD Has Largest 188 Staffers Tapping Option: Poll
May 9, 2023
- Eisai, BlissBio to Codevelop ADC Using Eribulin
May 9, 2023
- Sumitomo Gears Up for Post-Latuda Growth, Sets 2027 Target Sales to 600 Billion Yen
May 8, 2023
- Sumitomo’s Projected Operating Loss Widens on Ditched Cancer Med, US Realignment
May 8, 2023
- Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
May 8, 2023
- Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
- Meiji Files CSL Seqirus’ mRNA COVID Vaccine in Japan
May 1, 2023
- FDA Accepts BLA Re-Submission for Takeda’s Entyvio SC
May 1, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…